The Results of Pilot Study of the Mesenchymal Stem Cells Efficiency for Induction of Immunosuppressive Therapy in the Early Postoperative Period after Kidney Transplantation

Cell therapy with intravascular administration of mesenchymal stromal cells continues to appear safe: An updated systematic review and meta-analysis

“…1 for PRISMA flow diagram). All 55 RCTs were included for review (n = 2696 patients) [18À66] ( Table 1); six of the 55 RCTs were published in abstract form only [19,45,61,64,65,67]. Included RCTs were conducted in 12 different countries and 20 (36¢4%) were multi-center [20À23, 26,27,29,38,40,46,47,49,55,62À64,66,68À70].…”

“…Patient populations were diverse and included cardiovascular (12 trials, n = 612 patients) [21,24À27,29,37,40,42,44,49,58], neurological (10 trials, n = 242 patients) [30À32, 36,45,48,57,62,65,69], renal (three trials, n = 177 patients) [55,63,67], liver (seven trials, n = 404 patients) [35,43,47,53,54,59,66], respiratory (three trials, n = 134 patients) [18,23,68] and endocrine diseases (four trials, n = 169 patients) [22,28,39,50], hematological/oncological malignancies (five trials, n = 318 patients) [33,34,41,46,71], immune deficient or inflammatory conditions (nine trials, n = 544 patients) [20,38,51,52,60,61,64,70,72], general frailty (one trial, n = 30 patients) [56], and severe sepsis in severely neutropenic patients with hematologic malignancies (one trial, n = 30 patients) [19].…”

“…With respect to MSC preparation and administration, of the 55 included RCTs, 31 (56¢4%) examined bone marrow [19,21-27,29-34,36,39,41-43,45,47,53,55À59,61,66,68,71], 16 (29¢1%) umbilical cord [28,35,38,40,44,46,[48][49][50][51][52]54,60,63,65,72], four (7¢3%) adipose-derived MSCs [18,20,62,64], two (3¢6%) placenta-derived cells [69,70]; and in two RCT (3¢6%) the source of MSCs was unclear [37,67]. See Supplementary Table 1 [33,34,41,67]. Two (3¢6%) RCTs used placentaderived mesenchymal-like cells [69,70] and one (1¢8%) RCT used mesenchymal precursor cells (MPC) rather than MSCs [22].…”

“…Two (3¢6%) RCTs used placentaderived mesenchymal-like cells [69,70] and one (1¢8%) RCT used mesenchymal precursor cells (MPC) rather than MSCs [22]. Twelve (21¢8%) RCTs cultured the MSCs in a xeno-free medium [21,27,28,39 , two (3¢6%) used both a fresh and cryopreserved product [41,71] and in six (10¢9%) it was unclear [36,37,45,61,65,67]. One trial that used both a fresh and cryopreserved product (1¢8%) [71] and five of the 32 RCTs that used fresh MSCs (9¢1%) used a cryopreserved cell product that was thawed and cultured prior to injection for a fresh cell product [18,47,49,68,72].…”

Application of Mesenchymal Stem Cells for the Treatment of Liver Graft Dysfunction Caused by Chronic Rejection. Case Report

“…Учитывая данные современной литературы [7,8] и накопленный опыт в ГУ «Минский научно-практический центр хирургии, трансплантологии и гематологии» по использованию клеточных биотехнологий у пациентов после трансплантации солидных органов [9][10][11], для поддержания глубины иммуносупрессивной терапии и создания толерогенного фона пациентке был применен альтернативный вариант иммуносупрессивной терапии -мезенхимальные стволовые клетки (МСК). Источником МСК послужила жировая ткань, полученная от доноров со смертью мозга (биомедицинский клеточный продукт «Клетки мезенхимальные человека ТУ BY 100660677.001»).…”